RBC Capital Maintains Outperform on IDEAYA Biosciences, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Negative 95.3%

Neg 95.3% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains IDEAYA Biosciences (NASDAQ:IDYA) with a Outperform and lowers the price target from $53 to $48.